Published in Liver Transpl Surg on November 01, 1997
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology (2013) 1.67
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Liver transplantation in alcoholic liver disease current status and controversies. World J Gastroenterol (2013) 1.30
Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22
Therapy for alcoholic liver disease. World J Gastroenterol (2014) 1.17
Little response of cerebral metastasis from hepatocellular carcinoma to any treatments. J Korean Neurosurg Soc (2010) 1.02
New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother (2013) 1.01
MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World J Gastroenterol (2005) 0.98
Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor. BMC Cancer (2013) 0.98
Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. World J Gastroenterol (2014) 0.92
Model for End-stage Liver Disease. J Clin Exp Hepatol (2012) 0.92
Liver transplantation for alcoholic liver disease. World J Gastroenterol (2010) 0.91
Indications and contraindications for liver transplantation. Int J Hepatol (2011) 0.88
KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol (2013) 0.87
Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol (2011) 0.84
Usefulness of C-reactive protein for evaluating clinical outcomes in cirrhotic patients with bacteremia. Korean J Intern Med (2011) 0.82
Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol (2016) 0.80
Alcoholic liver disease: treatment. World J Gastroenterol (2014) 0.79
Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls. Clin Pharmacol Drug Dev (2013) 0.78
Challenges in transplantation for alcoholic liver disease. World J Gastroenterol (2014) 0.78
Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2015) 0.78
Advances in liver transplantation allocation systems. World J Gastroenterol (2016) 0.78
Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review. Alcohol Clin Exp Res (2016) 0.77
Ethnic disparities in liver transplantation. Gastroenterol Hepatol (N Y) (2011) 0.77
Liver transplantation for alcoholic liver disease: Lessons learned and unresolved issues. World J Gastroenterol (2015) 0.77
Liver transplantation(). J Ultrasound (2007) 0.77
Treatment of decompensated alcoholic liver disease. Int J Hepatol (2011) 0.76
Continued Smoking in Lung Transplant Patients: A Cross Sectional Survey. Zdr Varst (2015) 0.75
Oral health and liver function in children and adolescents with cirrhosis of the liver. Prz Gastroenterol (2014) 0.75
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients. Exp Ther Med (2016) 0.75
A comprehensive validation of HBV-related acute-on-chronic liver failure models to assist decision-making in targeted therapeutics. Sci Rep (2016) 0.75
Risk of alcohol use relapse after liver transplantation for alcoholic liver disease. World J Gastroenterol (2017) 0.75
Ohio solid organ transplantation consortium criteria for liver transplantation in patients with alcoholic liver disease. World J Hepatol (2016) 0.75
Current advances in liver transplantation. Ochsner J (1999) 0.75
A collective wisdom. Liver Transpl Surg (1997) 0.75
Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada. Can J Gastroenterol Hepatol (2016) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med (2000) 18.26
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
The repair of double-strand breaks in the nuclear DNA of Saccharomyces cerevisiae and its genetic control. Mol Gen Genet (1976) 6.89
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Nucleotide sequence of the tetM tetracycline resistance determinant of the streptococcal conjugative shuttle transposon Tn1545. Nucleic Acids Res (1986) 4.47
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science (1982) 4.07
A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
MELD and PELD: application of survival models to liver allocation. Liver Transpl (2001) 3.76
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
A type VII myosin encoded by the mouse deafness gene shaker-1. Nature (1995) 3.71
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology (1980) 3.57
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 3.45
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med (1996) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry (1995) 3.30
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell (2001) 3.05
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology (1996) 2.94
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Islet isolation assessment in man and large animals. Acta Diabetol Lat (1991) 2.89
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Dynamic actin-based epithelial adhesion and cell matching during Drosophila dorsal closure. Curr Biol (2000) 2.78
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.69
Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant (2014) 2.67
A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol (1997) 2.65
Mechanisms of epithelial fusion and repair. Nat Cell Biol (2001) 2.63
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Failure of silicone gel breast implants: analysis of literature data for 1652 explanted prostheses. Plast Reconstr Surg (1997) 2.56
Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J (1984) 2.55
Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes (2001) 2.51
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology (1980) 2.39
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther (2013) 2.38
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
Current concepts. Primary sclerosing cholangitis. N Engl J Med (1984) 2.35
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature (1995) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium (2000) 2.32
Right lobe living donor liver transplantation. Transplantation (1999) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
High risk of sensitization after failed islet transplantation. Am J Transplant (2007) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl (2000) 2.27
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood (2001) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Safeguards for research using large scale DNA collections. BMJ (2000) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology (1989) 2.19
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.17
An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin-embedded tissues. Med Mycol (2001) 2.16
Normoglycaemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1991) 2.15
Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat (2013) 2.15
Putting ion channels to work: mechanoelectrical transduction, adaptation, and amplification by hair cells. Proc Natl Acad Sci U S A (2000) 2.15
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene. Science (1984) 2.12
Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. J Cell Biol (1996) 2.12
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology (1994) 2.10